Florian Plattner

Florian Plattner

Auto-generated profile, based on publicly available information

Florian Plattner

Department of Psychiatry, The University of Texas Southwestern Medical Center, Dallas, TX, USA

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2006 in Journal of Biological Chemistry
Verified
Journal Article
Open access
FPFlorian Plattner
Florian Plattner
MAMarco Angelo
Marco Angelo
KGK. Peter Giese
K. Peter Giese
Hyperphosphorylation of the microtubule-associated protein tau is a characteristic feature of neurodegenerative tauopathies including Alzheimer disease. Over-activation of proline-directed kinases, such as cyclin-dependent kinase 5 (Cdk5) and glycogen synthase kinase 3 (GSK3), has been implicated in the aberrant phosphorylation of tau at proline-directed sites. In this study we tested the roles of Cdk5 and GSK3 in tau hyperphosphorylation in vivo using transgenic mice with p25-induced Cdk5 over-activation. We found that over-activation of Cdk5 in young transgenic animals does not induce tau hyperphosphorylation at sites recognized by the antibodies AT8, AT100, PHF-1, and TG3. In fact, we observed that Cdk5 over-activation leads to inhibition of GSK3. However, in old transgenic animals the inhibition of GSK3 is lost and results in increased GSK3 activity, which coincides with tau hyperphosphorylation at the AT8 and PHF-1 sites. Pharmacological inhibition of GSK3 in old transgenic mice by chronic treatment with lithium leads to a reduction of the age-dependent increase in tau hyperphosphorylation. Furthermore, we found that Cdk5, GSK3, and PP2A co-immunoprecipitate, suggesting a functional association of these molecules. Together, these results reveal the role of GSK3 as a key mediator of tau hyperphosphorylation, whereas Cdk5 acts as a modulator of tau hyperphosphorylation via the inhibitory regulation of GSK3. Furthermore, these findings suggest that disruption of regulation of GSK3 activity underlies tau hyperphosphorylation in neurodegenerative tauopathies. Hence, GSK3 may be a prime target for therapeutic intervention in tauopathies including Alzheimer disease.

12 January 2007 in European Journal of Neuroscience
Verified
Journal Article
Closed access
PDF file
CHClaudie Hooper
Claudie Hooper
VMVladimir Markevich
Vladimir Markevich
FPFlorian Plattner
Florian Plattner
RKRichard Killick
Richard Killick
ESEmma Schofield
Emma Schofield
SLSimon Lovestone
Simon Lovestone

17 July 2007 in Journal of Neurochemistry
Verified
Journal Article
Closed access
PDF file
ACAdam R. Cole
Adam R. Cole
WNWendy Noble
Wendy Noble
LALidy van Aalten
Lidy van Aalten
FPFlorian Plattner
Florian Plattner
RMRena Meimaridou
Rena Meimaridou
CSCalum Sutherland
Calum Sutherland

1 October 2013 in Cancer Cell
Verified
Journal Article
Closed access
KPKarine Pozo
Karine Pozo
ECEmely Castro-Rivera
Emely Castro-Rivera
CTChunfeng Tan
Chunfeng Tan
FPFlorian Plattner
Florian Plattner
GSGert Schwach
Gert Schwach
JBJames A. Bibb
James A. Bibb

1 September 2017 in Cell Reports
Verified
Journal Article
Open access
BEBret Michael Evers
Bret Michael Evers
CRCarlos Rodriguez-Navas
Carlos Rodriguez-Navas
RTRachel J. Tesla
Rachel J. Tesla
JPJanine Prange-Kiel
Janine Prange-Kiel
CWCatherine R. Wasser
Catherine R. Wasser
JHJoachim Herz
Joachim Herz
Defective lysosomal function defines many neurodegenerative diseases, such as neuronal ceroid lipofuscinoses (NCL) and Niemann-Pick type C (NPC), and is implicated in Alzheimer's disease (AD) and frontotemporal lobar degeneration (FTLD-TDP) with progranulin (PGRN) deficiency. Here, we show that PGRN is involved in lysosomal homeostasis and lipid metabolism. PGRN deficiency alters lysosome abundance and morphology in mouse neurons. Using an unbiased lipidomic approach, we found that brain lipid composition in humans and mice with PGRN deficiency shows disease-specific differences that distinguish them from normal and other pathologic groups. PGRN loss leads to an accumulation of polyunsaturated triacylglycerides, as well as a reduction of diacylglycerides and phosphatidylserines in fibroblast and enriched lysosome lipidomes. Transcriptomic analysis of PGRN-deficient mouse brains revealed distinct expression patterns of lysosomal, immune-related, and lipid metabolic genes. These findings have implications for the pathogenesis of FTLD-TDP due to PGRN deficiency and suggest lysosomal dysfunction as an underlying mechanism.

1 March 2014 in Neuron
Verified
Journal Article
Closed access
FPFlorian Plattner
Florian Plattner
AHAdan Hernández
Adan Hernández
TKTara M. Kistler
Tara M. Kistler
KPKarine Pozo
Karine Pozo
PZPing Zhong
Ping Zhong
JBJames A. Bibb
James A. Bibb